Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571649 · ClinicalTrials.gov registry record · Phase 3
Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,101
- Enrollment target
NCT00571649 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 8,101 participants.
The verdict
NCT00571649, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,101 participants
- Enrollment target
Study Summary
This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the standard enoxaparin dose and duration regimen. The safety of rivaroxaban will also be studied.
Interventions
- DRUG Enoxaparin
- DRUG Rivaroxaban (Xarelto, BAY59-7939)
- DRUG Rivaroxaban placebo
- DRUG Enoxaparin placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,101 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00571649
The ClinicalTrials.gov registry entry for NCT00571649 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8,101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Enoxaparin is the first listed.
NCT00571649 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00571649 about?
NCT00571649 is a clinical study titled "Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients". This study will evaluate if extended therapy with oral rivaroxaban can prevent blood clots in the leg and lung that can occur with patients hospitalized for acute medical illness, and compare these results with those of the standard enoxaparin dose and duration regimen. The safety of rivaroxaban wil...
What is the current status of trial NCT00571649?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,101 participants. The study started on 2007-12. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00571649?
The interventions under investigation include: Enoxaparin (DRUG), Rivaroxaban (Xarelto, BAY59-7939) (DRUG), Rivaroxaban placebo (DRUG), Enoxaparin placebo (DRUG).
Who is sponsoring clinical trial NCT00571649?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.